Susquehanna International Group’s InMed Pharmaceuticals INM Stock Holding History

Susquehanna International Group’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,753	Closed	-$13.5K	–	13604
2025 Q4	$13.5K	Buy	+12,753	New	+$21.2K	﹤0.01%	12022
2023 Q4	–	Sell	-1,329	Closed	-$18.3K	–	12808
2023 Q3	$18.3K	Buy	1,329 +645	+94%	+$11.8K	﹤0.01%	11623
2023 Q2	$12.6K	Sell	684 -257	-27%	-$6.22K	﹤0.01%	11724
2023 Q1	$20.3K	Buy	+941	New	+$30.4K	﹤0.01%	12047

Other funds holding INM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $431M AUM 20.62% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Susquehanna International Group's INM Position: Q1 2026 in Review

Susquehanna International Group sold out of InMed Pharmaceuticals (INM) in Q1 2026, closing a stake of 12,753 shares — an estimated $13.5K sold.

Susquehanna International Group first reported a position in INM in Q1 2023 and held it in 4 quarters. The position peaked at $20.3K in Q1 2023. 9 funds tracked by Wall St. Rank hold INM as of Q1 2026.

Susquehanna International Group reported no remaining InMed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Susquehanna International Group sold 12,753 InMed Pharmaceuticals shares in Q1 2026, an estimated $13.5K.
Susquehanna International Group first reported a position in InMed Pharmaceuticals in Q1 2023 and held it in 4 quarters.
Susquehanna International Group's InMed Pharmaceuticals position peaked at $20.3K in Q1 2023.
9 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.